Gene Expressions: The HER Pathway and Cancer

In the 1980s, Genentech scientists, working with colleagues elsewhere made a fundamental discovery of why certain breast cancers were very aggressive.

The discovery of an excess of HER2 activity in breast cancer changed the way the disease was defined and researched. It was a discovery that led to hundreds of clinical trials and remains a very active area of research today. Genentech VP of Clinical Oncology Dietmar Berger explains the role of the HER Pathway in cancer.